Table 2. Multivariable predictive model of adverse evolution within COVID 19 patients

|  |  |  |  |
| --- | --- | --- | --- |
| **Variables** | **OR (99% CI)** | **p** | **Score** |
| *Sociodemographic variables* |  |  |  |
| **Gender** |  |  |  |
| Female | Ref | - | - |
| Male | 1.99 (1.85-2.15) | <0.0001 | 4 |
| **Age (years) categorized** |  |  |  |
| < 30 | Ref | - | - |
| 30-39 | 4.48 (2.77-7.24) | <0.0001 | 9 |
| 40-49 | 7.33 (4.69-11.47) | <0.0001 | 12 |
| 50-59 | 15.37 (9.96-23.71) | <0.0001 | 16 |
| 60-69 | 37.5 (24.45-57.5) | <0.0001 | 21 |
| 70-79 | 68.46 (44.66-104.94) | <0.0001 | 25 |
| 80-89 | 110.42 (71.92-169.52) | <0.0001 | 27 |
| >= 90 | 209.17 (135.5-322.88) | <0.0001 | 31 |
| *Comorbidities* |  |  |  |
| **Cerebrovascular disease** | 1.28 (1.17-1.41) | <0.0001 | 1 |
| **Dementia** | 2.26 (2.03-2.52) | <0.0001 | 5 |
| **Diabetes** |  |  |  |
| No | Ref | - | - |
| Yes, without organ damage | 1.34 (1.22-1.47) | <0.0001 | 2 |
| Yes, with organ damage | 1.74 (1.48-2.03) | <0.0001 | 3 |
| **Kidney** | 1.51 (1.37-1.66) | <0.0001 | 2 |
| **Interstitial lung disease** | 2.42 (1.7-3.45) | <0.0001 | 5 |
| **Tumor** | 1.85 (1.66-2.07) | <0.0001 | 4 |
| **Heart disease1** | 1.4 (1.26-1.56) | <0.0001 | 2 |
| **Heart failure2** | 1.5 (1.34-1.67) | <0.0001 | 2 |
| *Basic treatments* |  |  |  |
| **Diuretics** | 1.19 (1.07-1.31) | 0.001 | 1 |
| **Chronic systemic steroids** | 2.51 (2.2-2.85) | <0.0001 | 5 |
|  | **Train (99%CI)** | **Test (99%CI)** | **Omicron (99%CI)** |
| **AUC** | 0.8963 (0.8900 – 0.9027) | 0.8888 (0.8820 – 0.8956) | 0.9128 (0.9017 – 0.9240) |
| **AUC\_score\_cont** | 0.8961 (0.8897 – 0.9024) | 0.8886 (0.8818 – 0.8953) | 0.9133 (0.8989 – 0.9278) |
| **AUC\_score\_cate (14, 21, 29)** | 0.8789 (0.8722 – 0.8856) | 0.8717 (0.8646 – 0.8788) | 0.8990 (0.8841 – 0.9138) |